JCI: No need to diet and exercise!

Obesity is one of the ten chronic diseases identified by the World Health Organization.

Obesity is both a feature and a disease.

October 7, 2021, researchers at Johns Hopkins University in the Journal of Clinical Investigation published in the journal entitled: Inhibition of phosphodiesterase of the type of reduces [9 Obesity and cardiometabolic syndrome in the MICE research papers

The study found a drug that does not require diet and daily activity control.

Early studies have shown that the PDE9 enzyme exists in the heart and causes heart disease caused by high blood pressure.

Based on these results, researchers suspect that PDE9 inhibitors may improve cardiometabolic syndrome, including high blood pressure, high blood sugar, cholesterol and triglycerides, and obesity

To test the effects of PDE9 inhibitors on obesity and cardiometabolic syndrome, the researchers put mice on a high-fat diet.

For the next six to eight weeks, the mice were given oral PDE9 inhibitors or placebos

During the 8-week drug trial, mice taking placebo gained an average of 22% weight, while mice taking PDE9 inhibitors lost 5.

Mice taking PDE9 inhibitors lose weight, and what they lose is fat

Further analysis revealed that PDE9 inhibition produces these effects by activating the master regulator of fat metabolism (PPARa)

Not only that, the researchers also found that estrogen usually plays the role of PPARa in fat regulation in women, but when its level drops like after menopause, PPARa becomes more important for regulating fat, so the effect of inhibiting PDE9 is even greater.

In female mice with ovaries, no similar benefit was found

The researchers pointed out that if the results of the experiment are found to be suitable for humans, a 250-pound person can lose about 50 pounds by taking an oral PDE9 inhibitor without changing their diet or exercise habits

Original source:

Sumita Mishra, et al.